Apogee’s declared proposed guaranteed public offering

Image Credit: Yahoo Finance

Announcement 

Apogee Therapeutics Inc., a leading clinical-level biotechnology company accelerating optimization, novel biologics with standing ability for excellent profiles in the immunology and inflammatory (I and I) sector, has declared an underwritten public offering of shares of its common stock, instead a common stock, or in place of common stock to specific investors selectively and pre funded warrants to buy shares of its common stock.

This guaranteed public offering will bring stability and the trading cycle of the company, correlating to the upcoming development and initiatives. It will gain traction in the financing alignment and accelerate the advancement. This will help contribute the utmost to the biotech market and pave new way for innovation in the healthcare sector.

Alongside, Apogee wants to reward a 30-day option for underwriters to buy an additional 15% of the shares of its common stock at the cost of public offering, commissions, and less underwriting discounts. The proposed public offering is titled to market conditions and various conditions, with the assurance as to when or whether the offering will reach its completion, or as to the original terms or size of the offering.

All securities are granted by Apogee. The company plans to utilize the net proceeds from this latest offering with the saved cash equivalents, marketable securities, long-standing marketable securities, and cash. To further fund the preclinical studies, commercial readiness activities, manufacturing, and clinical trials in support of its antibody programs. Including capital expenditures, additional research and development activities, and working capital and general corporate purposes.

In detail of the proposed underwritten public offering

BTIG and Jefferies, BofA Securities, Guggenheim Securities, and TD Cowen will act as joint book-running managers for the proposed offering. The automatic required effective shelf registration statement based on these securities was registered with the Securities and Exchange Commission (SEC) on 12^th August 2024. This offering will come into force only by means of a written prospectus, encompassing a prospectus supplement, a part of an effective registration statement.

The copy of the accompanying prospectus and preliminary prospectus based on the offering can be fetched when available from Jefferies LLC at the address: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022. Also, it's available from BofA Securities, NC1-0220-02-24 at the address prospectus department, 201 North Tryon Street, Charlotte, NC 28255-0001. Other official email ID and contact details are available on the website mentioned below.